-
Founded only two years!
Time of Update: 2021-12-30
In addition, ZL82, a new class 1 chemical drug of JAK3 highly selective inhibitor, is expected to submit a clinical trial application before the end of 2021, and is expected to be approved for clinical research in March-April 2022.
-
The results of the transformation of a traditional pharmaceutical company are evident, and the company’s new drug R&D reports are frequent
Time of Update: 2021-12-30
On December 6, 2021, the group’s self-developed humanized anti-tumor necrosis factor type 2 receptor ( TNFR2) monoclonal antibody SIM0235 (SIM1811-03 injection) has obtained a drug clinical trial approval notice issued by the National Medical Products Administration of China, and it is planned to be used for the development of relapsed or refractory advanced solid tumors and cutaneous T-cell lymphoma (CTCL) ) Clinical trials .
-
300 billion pharmaceutical giants terminated equity incentives, and a new response is coming!
Time of Update: 2021-12-30
On the evening of December 8, Hengrui Medicine issued an announcement stating that the company’s board of directors has decided to terminate the implementation of the 2020 restricted stock incentive plan and repurchase and cancel related restricted stocks that have been granted but not yet lifted .
-
Within one day, the chain pharmacy giants newly invested in 2 pharmaceutical companies
Time of Update: 2021-12-29
On September 24, according to the company's investigation, Dashenlin increased its foreign investment.
Yun Kang Square pharmaceutical chain was founded in 2012, February 9, the registered capital of 6 million yuan, business scope, including Chinese Herbal Medicine, Chinese medicine, antibiotic preparations .
-
Within 1 day, Fosun Pharma had two related transactions
Time of Update: 2021-12-29
On December 10, Fosun Pharma issued two consecutive external investment and related-party transaction announcements.
Among them, Fosun Industrial, a subsidiary of Fosun Pharma, signed an "Equity Transfer Agreement" with Windgothenburg, a related party, and Fosun Industrial intends to invest US$28.
-
This pharmaceutical company has strong export of raw materials and sales growth has exceeded 40%
Time of Update: 2021-12-29
It is worth mentioning that since October this year, nearly 10 API products of Northeast Pharmaceutical have successively passed the quality audits of 12 important domestic and foreign customers .
-
Jointown Pharmaceutical has reached a strategic cooperation with Tianfang Pharmaceutical, which will help it accelerate its opening of the out-of-hospital market
Time of Update: 2021-12-29
It is understood that through this cooperation, Tianfang Pharmaceutical can obtain its comprehensive network and distribution service support, market maintenance, information value-added services, and cooperation with related varieties of centralized procurement .
-
Due to the dramatic change in performance, this pharmaceutical company plans to divest some of its pharmaceutical assets
Time of Update: 2021-12-29
Regarding the asset sale, the company stated that it is to gradually divest the pharmaceutical business, further improve and adjust the company's industry and investment structure, and focus more on the development of the new energy and new materials industry .
-
Shanghai Lu Xiangyi's high-speed refrigerated centrifuge assists the production and development of the new crown kit!
Time of Update: 2021-12-28
According to recent news, Shanghai Lu Xiangyi has supplied a batch of GL-21M high-speed refrigerated centrifuges to manufacturers of Covid-19 kits, further cheering for Covid-19 kit manufacturers to meet the market’s rapid and accurate testing needs .
-
How can pharmaceutical companies avoid the problem of flying dust?
Time of Update: 2021-12-28
From the perspective of the structure of the equipment, the complete equipment of Runshu Machinery's dust-free feeding station is composed of a dust removal system, an operating system, and a blanking and screening system .
-
This Chinese medicine giant has changed two chairmanships within one year!
Time of Update: 2021-12-27
According to the data, in May 1999, senior economist Pan Jie joined Pien Tze Huang as the deputy factory director of the pharmaceutical factory, and then worked competently until he left in December 2014.
In addition, when Pan Jie took office, the total market value of Pien Tze Huang was about 200 billion yuan, and then soared.
-
Since the beginning of this year, this pharmaceutical company has transferred the equity of 4 holding companies
Time of Update: 2021-12-27
Recently, Kang Enbei issued an announcement stating that the transfer of 42% of the shares of the subsidiary Cherish Ming, the current consortium consisting of five companies including Zhongsheng Pharmaceutical will be transferred with a total consideration of 1.
-
130 million yuan, this pharmaceutical company plans to sell a subsidiary of medical consumables
Time of Update: 2021-12-26
Recently, Minxiang Pharmaceutical issued an announcement stating that it intends to sell 100% equity of Tianjin Taishikang Medical Technology Co.
On August 31 this year, Tosun has issued an announcement revealing that it is planning a major asset sale and intends to transfer to Guangdong Dongyang Pharmaceutical Co.
-
Apple's mobile phone is discontinued due to food poisoning
Time of Update: 2021-12-25
According to MacRumors, Reuters stated that the iPhone 12 production in India has been halted due to a food poisoning incident at the Foxconn plant .
Foxconn's factory producing iPhone 12 models near Chennai in southern India will continue to close this week due to worker protests .
-
BeiGene and Novartis expand cooperation!
Time of Update: 2021-12-25
According to the agreement, in terms of ociperlimab, BeiGene will receive a cash advance of US$300 million from Novartis after the cooperation between the two parties, and Novartis will exercise its exclusive, time-based The option to obtain an additional 600 million or 700 million US dollars in payment, but this depends on obtaining the required antitrust approval .
-
Two centers land in Xuhui, Shanghai!
Time of Update: 2021-12-25
Recently, it was reported that Yasheng Pharmaceutical, a leading company based in China and facing the world, has officially settled in Xuhui, Shanghai with its two major centers of marketing and clinical medicine, and will start the process of commercialization .
-
In order to focus on precise diagnosis and treatment of cardiovascular diseases, this medical company has signed a number of cooperation agreements in the near future
Time of Update: 2021-12-25
At present, the platform function of its vascular interventional surgical robot and the advanced concept of unmanned operating room have attracted the attention of many domestic and foreign technology companies, and they have proposed to establish a strategic partnership with Runmed Medical .
-
Deeply cultivate SPE materials and build a national brand
Time of Update: 2021-12-25
Founded in 1997, Anpu Experiment is a leading enterprise integrating R&D, production, sales and service in the field of experimental materials in the inspection and testing industry in China.
-
For 420 million yuan, Jingxin Pharmaceutical acquired two traditional Chinese medicine companies
Time of Update: 2021-12-08
It is worth mentioning that, on June 21 this year, Jingxin Pharmaceutical also issued an announcement stating that in order to effectively increase the production capacity of Chinese medicine preparations and realize the industrial structure upgrade of the company’s traditional Chinese medicine business segment, the company’s wholly-owned subsidiary Inner Mongolia Jingxin intends to locate in Bayan.
-
3.723 billion yuan!
Time of Update: 2021-12-08
For this transaction, Dongyang said that the company will no longer engage in the production and sales of pharmaceutical-related products; In the future, it will actively expand new businesses in the fields of new energy such as variable frequency energy storage and new energy vehicles .
